Neuromelanin‐sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in <i>de novo</i> Parkinson's disease and its phenotypes

Wang, J; Li, Y; Huang, Zhemin; Wan, Wenbin; Zhang, Y; Wang, C; Cheng, Xiaoqin; Ye, F; Liu, K; Fei, G; Zeng, Mengsu; Jin, Lirong

doi:10.1111/ene.13628

Cited by 76 publications

(86 citation statements)

References 41 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and Y.F.) was 0.833 for the average CNR of the LC, indicating good to excellent intra‐ and interrater agreement of LC measurements, consistent with our previous report …”

Section: Methodssupporting

confidence: 91%

See 1 more Smart Citation

Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus

Wang

et al. 2019

Movement Disorders

View full text Add to dashboard Cite

Background We aimed to investigate neuromelanin‐sensitive magnetic resonance imaging (NM‐MRI) features in the locus coeruleus of de novo Parkinson's disease patients with different cognitive states and to determine whether these features are associated with cognitive impairment. Methods Three groups of subjects were recruited in this study, including patients with de novo PD with mild cognitive impairment (n = 23), patients with de novo PD without cognitive impairment (n = 48), and control subjects (n = 32). All subjects underwent clinical evaluations, as well as MRI scanning. The contrast‐to‐noise ratio of the locus coeruleus in the neuromelanin‐sensitive MRI images and cortical thickness were measured. Results The contrast‐to‐noise ratio of the locus coeruleus in PD patients with mild cognitive impairment was significantly lower than that of controls (P = 0.016). The contrast‐to‐noise ratio of the locus coeruleus for PD patients without cognitive impairment was intermediate between that of controls and PD patients with mild cognitive impairment. Furthermore, multiple linear regression analysis showed that the contrast‐to‐noise ratio of the locus coeruleus was negatively associated with performance on the Trail Making Test B in all PD patients, controlling for age, sex, years of education, the Unified Parkinson's Disease Rating Scale motor scores from right upper limb, Geriatric Depression Rating Scales scores, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire scores, and cortical thickness. Conclusions Dysfunction of the locus coeruleus neurons may partly contribute to the decline in executive function in early de novo PD. In the future, the locus coeruleus‐norepinephrine system might be targeted for early‐intervention strategies in PD patients. © 2019 International Parkinson and Movement Disorder Society

show abstract

“…and Y.F.) was 0.833 for the average CNR of the LC, indicating good to excellent intra‐ and interrater agreement of LC measurements, consistent with our previous report …”

Section: Methodssupporting

confidence: 91%

“…All NM‐MR images were transferred to a workstation (ADW 4.6; GE Healthcare) for analysis, according to our previous study . One of the authors (a neuroradiologist with 10 years of experience [W.J.…”

Section: Methodsmentioning

confidence: 99%

Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus

Wang

et al. 2019

Movement Disorders

View full text Add to dashboard Cite

show abstract

“…We did not demonstrate any differences in SI norm between the two groups; however, several studies show a decreased SI SN in patients with PD compared to HC [18][19][20][21][22][23][24][25][26][27][28]. We might fail to demonstrate any difference in SI norm due to the small sample size.…”

Section: Discussioncontrasting

confidence: 81%

“…In 1986, Duguid et al [17] observed a reduced width of SN pars compacta in patients with PD using a 1.5T scanner. Since then, several MR studies report a decrease in signal intensity [18][19][20][21][22][23][24][25][26][27][28] and volume or surface reduction [19,21,22,25,26,[28][29][30][31][32][33][34] of the SN in patients with PD. Moreover, discrimination between PD patients and other Parkinsonian syndromes also yields reliable results [29,35,36].…”

Section: Introductionmentioning

confidence: 99%

Semi-Automatic Signature-Based Segmentation Method for Quantification of Neuromelanin in Substantia Nigra

et al. 2019

View full text Add to dashboard Cite

In Parkinson’s disease (PD), there is a reduction of neuromelanin (NM) in the substantia nigra (SN). Manual quantification of the NM volume in the SN is unpractical and time-consuming; therefore, we aimed to quantify NM in the SN with a novel semi-automatic segmentation method. Twenty patients with PD and twelve healthy subjects (HC) were included in this study. T1-weighted spectral pre-saturation with inversion recovery (SPIR) images were acquired on a 3T scanner. Manual and semi-automatic atlas-free local statistics signature-based segmentations measured the surface and volume of SN, respectively. Midbrain volume (MV) was calculated to normalize the data. Receiver operating characteristic (ROC) analysis was performed to determine the sensitivity and specificity of both methods. PD patients had significantly lower SN mean surface (37.7 ± 8.0 vs. 56.9 ± 6.6 mm2) and volume (235.1 ± 45.4 vs. 382.9 ± 100.5 mm3) than HC. After normalization with MV, the difference remained significant. For surface, sensitivity and specificity were 91.7 and 95 percent, respectively. For volume, sensitivity and specificity were 91.7 and 90 percent, respectively. Manual and semi-automatic segmentation methods of the SN reliably distinguished between PD patients and HC. ROC analysis shows the high sensitivity and specificity of both methods.

show abstract

“…Although in vivo positron emission tomography imaging studies using non-specific ligands failed to identify the noradrenergic damage, more recent neuromelanin-sensitive magnetic resonance studies have found progressive loss of the LC signal in both idiopathic and genetic PD patients and even a lower signal in those PD patients with depressive symptoms (Sasaki et al, 2006;Castellanos et al, 2015;Schwarz et al, 2017;Wang et al, 2018). 18 F-dopa positron emission tomography imaging, as an index of monoaminergic nerve terminal function, have also demonstrated a reduced uptake in the LC, indicating progressive loss of noradrenergic terminal function (Pavese et al, 2011).…”

Section: Clinical Evidencementioning

confidence: 99%

The Noradrenergic System in Parkinson’s Disease

et al. 2020

View full text Add to dashboard Cite

Nowadays it is well accepted that in Parkinson's disease (PD), the neurodegenerative process occurs in stages and that damage to other areas precedes the neuronal loss in the substantia nigra pars compacta, which is considered a pathophysiological hallmark of PD. This heterogeneous and progressive neurodegeneration may explain the diverse symptomatology of the disease, including motor and non-motor alterations. In PD, one of the first areas undergoing degeneration is the locus coeruleus (LC). This noradrenergic nucleus provides extensive innervation throughout the brain and plays a fundamental neuromodulator role, participating in stress responses, emotional memory, and control of motor, sensory, and autonomic functions. Early in the disease, LC neurons suffer modifications that can condition the effectiveness of pharmacological treatments, and importantly, can lead to the appearance of common non-motor symptomatology. The noradrenergic system also exerts anti-inflammatory and neuroprotective effect on the dopaminergic degeneration and noradrenergic damage can consequently condition the progress of the disease. From the pharmacological point of view, it is also important to understand how the noradrenergic system performs in PD, since noradrenergic medication is often used in these patients, and drug interactions can take place when combining them with the gold standard drug therapy in PD, L-3,4-dihydroxyphenylalanine (L-DOPA). This review provides an overview about the functional status of the noradrenergic system in PD and its contribution to the efficacy of pharmacologicalbased treatments. Based on preclinical and clinical publications, a special attention will be dedicated to the most prevalent non-motor symptoms of the disease.

show abstract

Neuromelanin‐sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes

Cited by 76 publications

References 41 publications

Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus

Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus

Semi-Automatic Signature-Based Segmentation Method for Quantification of Neuromelanin in Substantia Nigra

The Noradrenergic System in Parkinson’s Disease

Contact Info

Product

Resources

About